{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:42:12Z","timestamp":1773232932102,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10147-025-02760-y","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:14:39Z","timestamp":1744283679000},"page":"1143-1151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Concordance of BRAF V600E mutation between immunohistochemistry and genomic testing for thyroid cancer"],"prefix":"10.1007","volume":"30","author":[{"given":"Ryutaro","family":"Onaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Enokida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Sakashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobukazu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuma","family":"Kishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Kuboki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nishino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genichiro","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumpei","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9035-3106","authenticated-orcid":false,"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"2760_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74:12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"key":"2760_CR2","unstructured":"(2016\u20132020) Cancer Statistics. Cancer Information Service, National Cancer Center, Japan. National Cancer Registry, Ministry of Health, Labour and Welfare"},{"key":"2760_CR3","unstructured":"National comprehensive cancer network clinical practice guidelines in oncology, Thyroid Carcinoma, version 4.2024."},{"key":"2760_CR4","unstructured":"American Joint Committee on C, Amin MB (2017) AJCC cancer staging manual, 8th edn. Springer"},{"key":"2760_CR5","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jss.2024.07.075","volume":"302","author":"BN Titanji","year":"2024","unstructured":"Titanji BN, Earley M, Kebebew E (2024) Trends in mortality for anaplastic thyroid cancer: have we made progress? J Surg Res 302:476\u2013483. https:\/\/doi.org\/10.1016\/j.jss.2024.07.075","journal-title":"J Surg Res"},{"key":"2760_CR6","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1007\/s12020-024-03738-y","volume":"85","author":"H Yamazaki","year":"2024","unstructured":"Yamazaki H, Kunisaki C, Sugimori M et al (2024) Genetic landscape of 482 thyroid carcinomas: analysis with the national datacenter for cancer genomic medicine in Japan. Endocrine 85:766\u2013776. https:\/\/doi.org\/10.1007\/s12020-024-03738-y","journal-title":"Endocrine"},{"key":"2760_CR7","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1210\/clinem\/dgae271","volume":"109","author":"S Toda","year":"2024","unstructured":"Toda S, Hiroshima Y, Iwasaki H et al (2024) Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan. J Clin Endocrinol Metab 109:2784\u20132792. https:\/\/doi.org\/10.1210\/clinem\/dgae271","journal-title":"J Clin Endocrinol Metab"},{"key":"2760_CR8","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/cen.15098","volume":"101","author":"Y Saito","year":"2024","unstructured":"Saito Y, Kage H, Kobayashi K et al (2024) Comprehensive genomic profiling from C-CAT database unveiled over 80% presence of oncogenic drivers in anaplastic thyroid carcinoma including BRAF, RAS family, NF1, and FGFR1. Clin Endocrinol (Oxf) 101:170\u2013179. https:\/\/doi.org\/10.1111\/cen.15098","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2760_CR9","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/thy.2022.0115","volume":"32","author":"NL Busaidy","year":"2022","unstructured":"Busaidy NL, Konda B, Wei L et al (2022) Dabrafenib versus dabrafenib + trametinib in BRAF-mutated radioactive iodine refractory differentiated thyroid cancer: results of a randomized, phase 2, open-label multicenter trial. Thyroid 32:1184\u20131192. https:\/\/doi.org\/10.1089\/thy.2022.0115","journal-title":"Thyroid"},{"key":"2760_CR10","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1089\/thy.2023.0547","volume":"34","author":"M Tahara","year":"2024","unstructured":"Tahara M, Kiyota N, Imai H et al (2024) A phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-mutated thyroid cancer in Japan. Thyroid 34:467\u2013476. https:\/\/doi.org\/10.1089\/thy.2023.0547","journal-title":"Thyroid"},{"key":"2760_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","volume":"33","author":"V Subbiah","year":"2022","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA et al (2022) Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol 33:406\u2013415. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.014","journal-title":"Ann Oncol"},{"key":"2760_CR12","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fonc.2017.00025","volume":"7","author":"M Tahara","year":"2017","unstructured":"Tahara M, Kiyota N, Yamazaki T et al (2017) Lenvatinib for anaplastic thyroid cancer. Front Oncol 7:25. https:\/\/doi.org\/10.3389\/fonc.2017.00025","journal-title":"Front Oncol"},{"key":"2760_CR13","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1089\/thy.2023.0553","volume":"34","author":"M Tahara","year":"2024","unstructured":"Tahara M, Takami H, Ito Y et al (2024) A prospective cohort study exploring the effect of lenvatinib planned drug holidays in treatment of differentiated thyroid cancer. Thyroid 34:566\u2013574. https:\/\/doi.org\/10.1089\/thy.2023.0553","journal-title":"Thyroid"},{"key":"2760_CR14","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa2005651","volume":"383","author":"LJ Wirth","year":"2020","unstructured":"Wirth LJ, Sherman E, Robinson B et al (2020) Efficacy of selpercatinib in RET-altered thyroid cancers. N Engl J Med 383:825\u2013835. https:\/\/doi.org\/10.1056\/NEJMoa2005651","journal-title":"N Engl J Med"},{"key":"2760_CR15","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","volume":"28","author":"GD Demetri","year":"2022","unstructured":"Demetri GD, De Braud F, Drilon A et al (2022) Updated integrated analysis of the efficacy and safety of entrectinib in patients with NTRK fusion-positive solid tumors. Clin Cancer Res 28:1302\u20131312. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3597","journal-title":"Clin Cancer Res"},{"key":"2760_CR16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1530\/EJE-21-1259","volume":"186","author":"SG Waguespack","year":"2022","unstructured":"Waguespack SG, Drilon A, Lin JJ et al (2022) Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma. Eur J Endocrinol 186:631\u2013643. https:\/\/doi.org\/10.1530\/EJE-21-1259","journal-title":"Eur J Endocrinol"},{"key":"2760_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"Bible KC, Kebebew E, Brierley J et al (2021) 2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 31:337\u2013386. https:\/\/doi.org\/10.1089\/thy.2020.0944","journal-title":"Thyroid"},{"key":"2760_CR18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s12022-024-09836-x","volume":"35","author":"O Mete","year":"2024","unstructured":"Mete O, Boucher A, Schrader KA et al (2024) Consensus statement: recommendations on actionable biomarker testing for thyroid cancer management. Endocr Pathol 35:293\u2013308. https:\/\/doi.org\/10.1007\/s12022-024-09836-x","journal-title":"Endocr Pathol"},{"key":"2760_CR19","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s12105-020-01166-8","volume":"14","author":"KG Parker","year":"2020","unstructured":"Parker KG, White MG, Cipriani NA (2020) Comparison of molecular methods and BRAF immunohistochemistry (VE1 clone) for the detection of BRAF V600E mutation in papillary thyroid carcinoma: a meta-analysis. Head Neck Pathol 14:1067\u20131079. https:\/\/doi.org\/10.1007\/s12105-020-01166-8","journal-title":"Head Neck Pathol"},{"key":"2760_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/his.12964","volume":"69","author":"S Rushton","year":"2016","unstructured":"Rushton S, Burghel G, Wallace A et al (2016) Immunohistochemical detection of BRAF V600E mutation status in anaplastic thyroid carcinoma. Histopathology 69:524\u2013526. https:\/\/doi.org\/10.1111\/his.12964","journal-title":"Histopathology"},{"key":"2760_CR21","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1001\/jamaoncol.2024.2133","volume":"10","author":"S Hamidi","year":"2024","unstructured":"Hamidi S, Dadu R, Zafereo ME et al (2024) Initial management of BRAF V600E-variant anaplastic thyroid cancer: the FAST multidisciplinary group consensus statement. JAMA Oncol 10:1264\u20131271. https:\/\/doi.org\/10.1001\/jamaoncol.2024.2133","journal-title":"JAMA Oncol"},{"key":"2760_CR22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00401-011-0841-z","volume":"122","author":"D Capper","year":"2011","unstructured":"Capper D, Preusser M, Habel A et al (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122:11\u201319. https:\/\/doi.org\/10.1007\/s00401-011-0841-z","journal-title":"Acta Neuropathol"},{"key":"2760_CR23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/ijms24044057","volume":"24","author":"A De Leo","year":"2023","unstructured":"De Leo A, Serban D, Maloberti T et al (2023) Expanding the spectrum of BRAF Non-V600E mutations in thyroid nodules: evidence-based data from a tertiary referral centre. Int J Mol Sci 24:9. https:\/\/doi.org\/10.3390\/ijms24044057","journal-title":"Int J Mol Sci"},{"key":"2760_CR24","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","volume":"21","author":"AJ Hanrahan","year":"2024","unstructured":"Hanrahan AJ, Chen Z, Rosen N et al (2024) BRAF\u2014a tumour-agnostic drug target with lineage-specific dependencies. Nat Rev Clin Oncol 21:224\u2013247. https:\/\/doi.org\/10.1038\/s41571-023-00852-0","journal-title":"Nat Rev Clin Oncol"},{"key":"2760_CR25","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/annonc\/mds534","volume":"24","author":"M Ilie","year":"2013","unstructured":"Ilie M, Long E, Hofman V et al (2013) Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients. Ann Oncol 24:742\u2013748. https:\/\/doi.org\/10.1093\/annonc\/mds534","journal-title":"Ann Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02760-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02760-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02760-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T01:11:01Z","timestamp":1748481061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02760-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["2760"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02760-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5969512\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MT reports grants and personal fees from Ono Pharmaceutical and Bayer, and personal fees from MSD, BMS, Merck Biopharma, Novartis, Pfizer, Rakuten Medical, Lilly, Boehringer Ingelheim, Eisai, Chugai Pharmaceutical, Daiichi-Sankyo, Janssen Pharmaceutical, Genmab, Astra Zeneca, Abbvie and Astellas, outside the submitted work. SO reports personal fees from Ono Pharmaceutical, MSD, BMS, and Merck Biopharma outside the submitted work. TF reports honoraria for lectures from Amelieff Co. Ltd. GI reports grants from Takeda Pharmaceutical Company Limited, Noile-Immune Biotech, Indivumed GmbH, Sumitomo Dainippon Pharma Co., Ltd. Nihon Medi-Physics CO., Ltd. ONO PHARMACEUTICAL CO., LTD. DAIICHI SANKYO, INC. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study protocol was approved by the Institutional Ethical Committee of the National Cancer Center Hospital East (reference number 2024-066). Written informed consent for participation was not required for this study, in accordance with national legislation and institutional requirements. Patients and their families were provided an opportunity to opt-out of the study in accordance with the policy of the Japanese government. The study was conducted in accordance with the principles laid down in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Statement"}}]}}